Dianosic launches a WiSEED backed convertible bonds transaction to accelerate innovation in the treatment of chronic allergic rhinitis. This initiative aims to support the…
Reinventing drug delivery via the intranasal route
Dianosic develops complex intranasal formulations and advanced drug-delivery solutions for
chronic respiratory diseases and central nervous system disorders.
Key highlights
01
Cutting-edge platform of intranasal, long-acting solid dosage forms
The DIAXX insert delivers a targeted, low dose of drug in a controlled manner for up to
12 months.
02
Significant potential across respiratory and neurological indications
Chronic allergic rhinitis (8M), chronic rhinosinusitis (5M) and CNS diseases via
Nose-to-Brain delivery (Schizophrenia, Parkinson — 23M) represent large adressable
markets.
03
Solving a critical adherence challenge
50% of patients do not adhere to their medications across therapeutic areas. Our "insert
and forget" approach guarantees 100% adherence.
04
€7M raised in 2025 — led by Aptar Pharma
Series A round with Aptar (Global drug delivery leader), Noshaq, Capital Grand Est and
Finovam Gestion to accelerate clinical development.
05
A complementary team
In-house Pharma and Medtech expertise supported by a Scientific Board composed of
world-renowned experts.